Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(6):952–958. doi: 10.1038/sj.bjc.6690792

Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells

L S Manning 1, N S Radin 2
PMCID: PMC2362950  PMID: 10576650

Abstract

This study describes the effects of the glucolipid synthase inhibitor P4, (DL-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol), on various functional and phenotypic parameters of 5T33 murine myeloma cells. Cell recovery was reduced by >85% following incubation of the cells for 3 days in the presence of 4 μM P4 (the IC50 concentration). Both cytostatic and cytotoxic inhibition was observed with tumour cell metabolic activity and clonogenic potential reduced to 42% and 14% of controls, respectively, and viability reduced to 52%. A dose-dependent increase in cells undergoing apoptosis (from 7% to 26%) was also found. P4 induced a decrease in the number of cells expressing H-2 Class I and CD44, and a large increase in cells expressing H-2 Class II and the IgG2b paraprotein. It did not affect surface expression of CD45 or CD54 (ICAM-1). Based on these alterations in tumour cell growth, adhesion molecule expression and potential immunogenicity, it is anticipated that P4 will provide a novel therapeutic approach for the treatment of multiple myeloma. In addition, given that essentially all tumours rely heavily on overexpressed or abnormal glucosphingolipids for growth, development and metastasis, glucolipid synthase inhibitors may prove to be universally effective anti-cancer agents. © 1999 Cancer Research Campaign

Keywords: P4 (DL-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol-HCl, multiple myeloma, growth inhibition, apoptosis, phenotypic markers

Full Text

The Full Text of this article is available as a PDF (101.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe A., Radin N. S., Shayman J. A. Induction of glucosylceramide synthase by synthase inhibitors and ceramide. Biochim Biophys Acta. 1996 Feb 16;1299(3):333–341. doi: 10.1016/0005-2760(95)00217-0. [DOI] [PubMed] [Google Scholar]
  2. Abe A., Radin N. S., Shayman J. A., Wotring L. L., Zipkin R. E., Sivakumar R., Ruggieri J. M., Carson K. G., Ganem B. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res. 1995 Mar;36(3):611–621. [PubMed] [Google Scholar]
  3. Armstrong T. D., Clements V. K., Martin B. K., Ting J. P., Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886–6891. doi: 10.1073/pnas.94.13.6886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Aruffo A., Stamenkovic I., Melnick M., Underhill C. B., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990 Jun 29;61(7):1303–1313. doi: 10.1016/0092-8674(90)90694-a. [DOI] [PubMed] [Google Scholar]
  5. Baskar S., Glimcher L., Nabavi N., Jones R. T., Ostrand-Rosenberg S. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med. 1995 Feb 1;181(2):619–629. doi: 10.1084/jem.181.2.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cabrera T., Ruiz-Cabello F., Garrido F. Biological implications of HLA-DR expression in tumours. Scand J Immunol. 1995 Apr;41(4):398–406. doi: 10.1111/j.1365-3083.1995.tb03584.x. [DOI] [PubMed] [Google Scholar]
  7. Cremer F. W., Kiel K., Wallmeier M., Goldschmidt H., Moos M. A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol. 1997 Jul;8(7):633–636. doi: 10.1023/a:1008286803199. [DOI] [PubMed] [Google Scholar]
  8. Croese J. W., Van den Enden-Vieveen M. H., Radl J. Immune regulation of 5T2 mouse multiple myeloma. II. Immunological treatment of 5T2 MM residual disease. Neoplasma. 1991;38(5):467–474. [PubMed] [Google Scholar]
  9. Croese J. W., Vissinga C. S., Boersma W. J., Radl J. Immune regulation of mouse 5T2 multiple myeloma. I. Immune response to 5T2 MM idiotype. Neoplasma. 1991;38(5):457–466. [PubMed] [Google Scholar]
  10. Dabadghao S., Bergenbrant S., Anton D., He W., Holm G., Yi Q. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol. 1998 Mar;100(4):647–654. doi: 10.1046/j.1365-2141.1998.00633.x. [DOI] [PubMed] [Google Scholar]
  11. Greipp P. R. Advances in the diagnosis and management of myeloma. Semin Hematol. 1992 Jul;29(3 Suppl 2):24–45. [PubMed] [Google Scholar]
  12. Hakomori S. Glycosphingolipids. Sci Am. 1986 May;254(5):44–53. doi: 10.1038/scientificamerican0586-44. [DOI] [PubMed] [Google Scholar]
  13. Hakomori S. Role of gangliosides in tumor progression. Prog Brain Res. 1994;101:241–250. doi: 10.1016/s0079-6123(08)61953-6. [DOI] [PubMed] [Google Scholar]
  14. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996 Dec 1;56(23):5309–5318. [PubMed] [Google Scholar]
  15. Ilangumaran S., Briol A., Hoessli D. C. CD44 selectively associates with active Src family protein tyrosine kinases Lck and Fyn in glycosphingolipid-rich plasma membrane domains of human peripheral blood lymphocytes. Blood. 1998 May 15;91(10):3901–3908. [PubMed] [Google Scholar]
  16. Inokuchi J., Jimbo M., Momosaki K., Shimeno H., Nagamatsu A., Radin N. S. Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action. Cancer Res. 1990 Oct 15;50(20):6731–6737. [PubMed] [Google Scholar]
  17. Inokuchi J., Mason I., Radin N. S. Antitumor activity via inhibition of glycosphingolipid biosynthesis. Cancer Lett. 1987 Dec;38(1-2):23–30. doi: 10.1016/0304-3835(87)90196-0. [DOI] [PubMed] [Google Scholar]
  18. Kannagi R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J. 1997 Aug;14(5):577–584. doi: 10.1023/a:1018532409041. [DOI] [PubMed] [Google Scholar]
  19. Klinken S. P. Erythroproliferation in vitro can be induced by abl, fes, src, ras, bas, raf, raf/myc, erb B and cbl oncogenes but not by myc, myb and fos. Oncogene Res. 1988 Sep;3(2):187–192. [PubMed] [Google Scholar]
  20. Kwak L. W., Campbell M. J., Czerwinski D. K., Hart S., Miller R. A., Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992 Oct 22;327(17):1209–1215. doi: 10.1056/NEJM199210223271705. [DOI] [PubMed] [Google Scholar]
  21. Kwak L. W., Taub D. D., Duffey P. L., Bensinger W. I., Bryant E. M., Reynolds C. W., Longo D. L. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet. 1995 Apr 22;345(8956):1016–1020. doi: 10.1016/s0140-6736(95)90757-2. [DOI] [PubMed] [Google Scholar]
  22. Kärre K. Natural killer cells and the MHC class I pathway of peptide presentation. Semin Immunol. 1993 Apr;5(2):127–145. doi: 10.1006/smim.1993.1016. [DOI] [PubMed] [Google Scholar]
  23. Lavie Y., Cao H., Bursten S. L., Giuliano A. E., Cabot M. C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem. 1996 Aug 9;271(32):19530–19536. doi: 10.1074/jbc.271.32.19530. [DOI] [PubMed] [Google Scholar]
  24. Li R., Villacreses N., Ladisch S. Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res. 1995 Jan 15;55(2):211–214. [PubMed] [Google Scholar]
  25. Manning L. S., Berger J. D., O'Donoghue H. L., Sheridan G. N., Claringbold P. G., Turner J. H. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer. 1992 Dec;66(6):1088–1093. doi: 10.1038/bjc.1992.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Manning L. S., Chamberlain N. L., Leahy M. F., Cordingley F. T. Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using the 5T33 murine myeloma model. Immunol Cell Biol. 1995 Aug;73(4):326–332. doi: 10.1038/icb.1995.50. [DOI] [PubMed] [Google Scholar]
  27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  28. Nakagawa R., Motoki K., Ueno H., Iijima R., Nakamura H., Kobayashi E., Shimosaka A., Koezuka Y. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res. 1998 Mar 15;58(6):1202–1207. [PubMed] [Google Scholar]
  29. Nudelman E., Levery S. B., Kaizu T., Hakomori S. Novel fucolipids of human adenocarcinoma: characterization of the major Ley antigen of human adenocarcinoma as trifucosylnonaosyl Ley glycolipid (III3FucV3FucVI2FucnLc6). J Biol Chem. 1986 Aug 25;261(24):11247–11253. [PubMed] [Google Scholar]
  30. Okado T., Hawley R. G. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int J Cancer. 1995 Dec 11;63(6):823–830. doi: 10.1002/ijc.2910630613. [DOI] [PubMed] [Google Scholar]
  31. Olshefski R., Ladisch S. Synthesis, shedding, and intercellular transfer of human medulloblastoma gangliosides: abrogation by a new inhibitor of glucosylceramide synthase. J Neurochem. 1998 Feb;70(2):467–472. doi: 10.1046/j.1471-4159.1998.70020467.x. [DOI] [PubMed] [Google Scholar]
  32. Radin N. S., Inokuchi J. Glucosphingolipids as sites of action in the chemotherapy of cancer. Biochem Pharmacol. 1988 Aug 1;37(15):2879–2886. doi: 10.1016/0006-2952(88)90271-7. [DOI] [PubMed] [Google Scholar]
  33. Radin N. S. Rationales for cancer chemotherapy with PDMP, a specific inhibitor of glucosylceramide synthase. Mol Chem Neuropathol. 1994 Feb-Apr;21(2-3):111–127. doi: 10.1007/BF02815346. [DOI] [PubMed] [Google Scholar]
  34. Radin N. S., Shayman J. A., Inokuchi J. Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances. Adv Lipid Res. 1993;26:183–213. [PubMed] [Google Scholar]
  35. Radl J., Croese J. W., Zurcher C., Van den Enden-Vieveen M. H., de Leeuw A. M. Animal model of human disease. Multiple myeloma. Am J Pathol. 1988 Sep;132(3):593–597. [PMC free article] [PubMed] [Google Scholar]
  36. Rosenwald A. G., Pagano R. E. Effects of the glucosphingolipid synthesis inhibitor, PDMP, on lysosomes in cultured cells. J Lipid Res. 1994 Jul;35(7):1232–1240. [PubMed] [Google Scholar]
  37. Schneider U., van Lessen A., Huhn D., Serke S. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol. 1997 Apr;97(1):56–64. doi: 10.1046/j.1365-2141.1997.d01-2115.x. [DOI] [PubMed] [Google Scholar]
  38. Sherman L., Sleeman J., Herrlich P., Ponta H. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol. 1994 Oct;6(5):726–733. doi: 10.1016/0955-0674(94)90100-7. [DOI] [PubMed] [Google Scholar]
  39. Tepper C. G., Jayadev S., Liu B., Bielawska A., Wolff R., Yonehara S., Hannun Y. A., Seldin M. F. Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8443–8447. doi: 10.1073/pnas.92.18.8443. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES